Literature DB >> 23817351

Neuro-oncology: in search of molecular markers of glioma in elderly patients.

Monika E Hegi, Roger Stupp.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23817351     DOI： 10.1038/nrneurol.2013.127

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

1.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.

Authors:  Jeremy Schwartzentruber; Andrey Korshunov; Xiao-Yang Liu; David T W Jones; Elke Pfaff; Karine Jacob; Dominik Sturm; Adam M Fontebasso; Dong-Anh Khuong Quang; Martje Tönjes; Volker Hovestadt; Steffen Albrecht; Marcel Kool; Andre Nantel; Carolin Konermann; Anders Lindroth; Natalie Jäger; Tobias Rausch; Marina Ryzhova; Jan O Korbel; Thomas Hielscher; Peter Hauser; Miklos Garami; Almos Klekner; Laszlo Bognar; Martin Ebinger; Martin U Schuhmann; Wolfram Scheurlen; Arnulf Pekrun; Michael C Frühwald; Wolfgang Roggendorf; Christoph Kramm; Matthias Dürken; Jeffrey Atkinson; Pierre Lepage; Alexandre Montpetit; Magdalena Zakrzewska; Krzystof Zakrzewski; Pawel P Liberski; Zhifeng Dong; Peter Siegel; Andreas E Kulozik; Marc Zapatka; Abhijit Guha; David Malkin; Jörg Felsberg; Guido Reifenberger; Andreas von Deimling; Koichi Ichimura; V Peter Collins; Hendrik Witt; Till Milde; Olaf Witt; Cindy Zhang; Pedro Castelo-Branco; Peter Lichter; Damien Faury; Uri Tabori; Christoph Plass; Jacek Majewski; Stefan M Pfister; Nada Jabado
Journal:  Nature       Date:  2012-01-29       Impact factor: 49.962

2.  Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

Authors:  Annika Malmström; Bjørn Henning Grønberg; Christine Marosi; Roger Stupp; Didier Frappaz; Henrik Schultz; Ufuk Abacioglu; Björn Tavelin; Benoit Lhermitte; Monika E Hegi; Johan Rosell; Roger Henriksson
Journal:  Lancet Oncol       Date:  2012-08-08       Impact factor: 41.316

3.  Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.

Authors:  Sameer Agnihotri; Aaron S Gajadhar; Christian Ternamian; Thierry Gorlia; Kristin L Diefes; Paul S Mischel; Joanna Kelly; Gail McGown; Mary Thorncroft; Brett L Carlson; Jann N Sarkaria; Geoffrey P Margison; Kenneth Aldape; Cynthia Hawkins; Monika Hegi; Abhijit Guha
Journal:  J Clin Invest       Date:  2011-12-12       Impact factor: 14.808

4.  TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.

Authors:  Patrick J Killela; Zachary J Reitman; Yuchen Jiao; Chetan Bettegowda; Nishant Agrawal; Luis A Diaz; Allan H Friedman; Henry Friedman; Gary L Gallia; Beppino C Giovanella; Arthur P Grollman; Tong-Chuan He; Yiping He; Ralph H Hruban; George I Jallo; Nils Mandahl; Alan K Meeker; Fredrik Mertens; George J Netto; B Ahmed Rasheed; Gregory J Riggins; Thomas A Rosenquist; Mark Schiffman; Ie-Ming Shih; Dan Theodorescu; Michael S Torbenson; Victor E Velculescu; Tian-Li Wang; Nicolas Wentzensen; Laura D Wood; Ming Zhang; Roger E McLendon; Darell D Bigner; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos; Hai Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

5.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.

Authors:  Dominik Sturm; Hendrik Witt; Volker Hovestadt; Dong-Anh Khuong-Quang; David T W Jones; Carolin Konermann; Elke Pfaff; Martje Tönjes; Martin Sill; Sebastian Bender; Marcel Kool; Marc Zapatka; Natalia Becker; Manuela Zucknick; Thomas Hielscher; Xiao-Yang Liu; Adam M Fontebasso; Marina Ryzhova; Steffen Albrecht; Karine Jacob; Marietta Wolter; Martin Ebinger; Martin U Schuhmann; Timothy van Meter; Michael C Frühwald; Holger Hauch; Arnulf Pekrun; Bernhard Radlwimmer; Tim Niehues; Gregor von Komorowski; Matthias Dürken; Andreas E Kulozik; Jenny Madden; Andrew Donson; Nicholas K Foreman; Rachid Drissi; Maryam Fouladi; Wolfram Scheurlen; Andreas von Deimling; Camelia Monoranu; Wolfgang Roggendorf; Christel Herold-Mende; Andreas Unterberg; Christof M Kramm; Jörg Felsberg; Christian Hartmann; Benedikt Wiestler; Wolfgang Wick; Till Milde; Olaf Witt; Anders M Lindroth; Jeremy Schwartzentruber; Damien Faury; Adam Fleming; Magdalena Zakrzewska; Pawel P Liberski; Krzysztof Zakrzewski; Peter Hauser; Miklos Garami; Almos Klekner; Laszlo Bognar; Sorana Morrissy; Florence Cavalli; Michael D Taylor; Peter van Sluis; Jan Koster; Rogier Versteeg; Richard Volckmann; Tom Mikkelsen; Kenneth Aldape; Guido Reifenberger; V Peter Collins; Jacek Majewski; Andrey Korshunov; Peter Lichter; Christoph Plass; Nada Jabado; Stefan M Pfister
Journal:  Cancer Cell       Date:  2012-10-16       Impact factor: 31.743

6.  Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective.

Authors:  Benedikt Wiestler; Rainer Claus; Sabine A Hartlieb; Maximilian G Schliesser; Elisa K Weiss; Thomas Hielscher; Michael Platten; Laura M Dittmann; Christoph Meisner; Jörg Felsberg; Caroline Happold; Matthias Simon; Guido Nikkhah; Kirsten Papsdorf; Joachim P Steinbach; Michael Sabel; Christiane Grimm; Dieter Weichenhan; Björn Tews; Guido Reifenberger; David Capper; Wolf Müller; Christoph Plass; Michael Weller; Wolfgang Wick
Journal:  Neuro Oncol       Date:  2013-04-17       Impact factor: 12.300

7.  Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.

Authors:  Wolfgang Wick; Michael Platten; Christoph Meisner; Jörg Felsberg; Ghazaleh Tabatabai; Matthias Simon; Guido Nikkhah; Kirsten Papsdorf; Joachim P Steinbach; Michael Sabel; Stephanie E Combs; Jan Vesper; Christian Braun; Jürgen Meixensberger; Ralf Ketter; Regine Mayer-Steinacker; Guido Reifenberger; Michael Weller
Journal:  Lancet Oncol       Date:  2012-05-10       Impact factor: 41.316

8.  Downregulation of PRDX1 by promoter hypermethylation is frequent in 1p/19q-deleted oligodendroglial tumours and increases radio- and chemosensitivity of Hs683 glioma cells in vitro.

Authors:  L M Dittmann; A Danner; J Gronych; M Wolter; K Stühler; M Grzendowski; N Becker; J Bageritz; V Goidts; G Toedt; J Felsberg; M C Sabel; S Barbus; G Reifenberger; P Lichter; B Tews
Journal:  Oncogene       Date:  2011-12-12       Impact factor: 8.756

9.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.

Authors:  Sevin Turcan; Daniel Rohle; Anuj Goenka; Logan A Walsh; Fang Fang; Emrullah Yilmaz; Carl Campos; Armida W M Fabius; Chao Lu; Patrick S Ward; Craig B Thompson; Andrew Kaufman; Olga Guryanova; Ross Levine; Adriana Heguy; Agnes Viale; Luc G T Morris; Jason T Huse; Ingo K Mellinghoff; Timothy A Chan
Journal:  Nature       Date:  2012-02-15       Impact factor: 69.504

10.  Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN.

Authors:  Lynn Bjerke; Alan Mackay; Meera Nandhabalan; Anna Burford; Alexa Jury; Sergey Popov; Dorine A Bax; Diana Carvalho; Kathryn R Taylor; Maria Vinci; Ilirjana Bajrami; Imelda M McGonnell; Christopher J Lord; Rui M Reis; Darren Hargrave; Alan Ashworth; Paul Workman; Chris Jones
Journal:  Cancer Discov       Date:  2013-05       Impact factor: 39.397
  10 in total
  2 in total

1.  A Cell-Surface Membrane Protein Signature for Glioblastoma.

Authors:  Dhimankrishna Ghosh; Cory C Funk; Juan Caballero; Nameeta Shah; Katherine Rouleau; John C Earls; Liliana Soroceanu; Greg Foltz; Charles S Cobbs; Nathan D Price; Leroy Hood
Journal:  Cell Syst       Date:  2017-03-29       Impact factor: 10.304

Review 2.  Management of elderly patients with glioblastoma-multiforme-a systematic review.

Authors:  Almadani Asmaa; Sanjay Dixit; Chris Rowland-Hill; Shailendra Achawal; Chitoor Rajaraman; Gerry O'Reilly; Robin Highley; Masood Hussain; Louise Baker; Lynne Gill; Holly Morris; Mohan Hingorani
Journal:  Br J Radiol       Date:  2018-03-09       Impact factor: 3.039
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.